49
* Related to Lipoprotein Goals for ASCVD Risk Reduction table.
†
Cardiovascular outcomes trials with inclisiran are pending.
ApoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary
artery calcium; HDL-C, high-density lipoprotein-cholesterol; HeFH, heterozygous familial
hypercholesterolemia; LDL-C, low-density lipoprotein-cholesterol; LLT, lipid-lowering therapy;
mAb, monoclonal antibody; and PCSK9, proprotein convertase subtilisin/kexin type 9.
Optional apoB goal
<55 mg/dL
2a
Add inclisiran
†
as
alternative to PCSK9 mAb
1
Add ezetimibe,
a PCSK9 mAb, and/or
bempedoic acid
Goal: LDL-C <55 mg/dL
and non–HDL-C <85 mg/dL
AND
AND
With clinical ASCVD*
